In order to meet the needs of rapid development of company, company plans to build a new pharmaceutical production base in zhihuiyuan, beicheng, gongshu district, with a total area of about 24 acres. Upon completion of the base, it will reach: Class III medical device production workshop produces 10 million medical (cross-linked) sodium hyaluronate gels per year, and Class I medical device production workshop produces 10 million medical cold compresses pcs/piece per year. Meanwhile, the production workshop of class II medical devices is reserved for the production of balloon and wound dressing. The base also includes medical device r&d pilot plant, drug production plant (reserved), quality control center, logistics center and so on. At present, land acquisition, preliminary design and key equipment selection have been completed, and construction is scheduled to be completed by the end of 2021.
Secondly, in order to fundamentally solve the problem of core raw material supply guarantee, establish complete industrial chain, the company controlling shareholder investment in new district of hangzhou qiantang river area construction of sodium hyaluronate raw materials production base, with a total area of about 85 acres, mainly engaged in the production of medical grade and cosmetic food grade sodium hyaluronate raw materials and cosmetics (hyaluronic acid mask and original liquid, etc.), It is planned to produce 500 kilograms of medical-grade sodium hyaluronate raw materials per year and 120 tons of cosmetic food-grade sodium hyaluronate raw materials to supply high-quality sodium hyaluronate raw materials for the company's medical sodium hyaluronate gel-related preparation products. The land acquisition has been completed.
R & D Pilot Plant
Quality Control Center